Cytoplasmic CPSF6 Regulates HIV-1 Capsid Trafficking and Infection in a Cyclophilin A-Dependent Manner

Zhou Zhong, Jiying Ning, Emerson A. Boggs, Sooin Jang, Callen Wallace, Cheryl Telmer, Marcel P. Bruchez, Jinwoo Ahn, Alan N. Engelman, Peijun Zhang, Simon C. Watkins, Zandrea Ambrose

Department of Microbiology and Molecular Genetics, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
Department of Structural Biology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
Department of Cell Biology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
Pittsburgh Center for HIV Protein Interactions, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA
Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA
Department of Biological Sciences, Carnegie Mellon University, Pittsburgh, Pennsylvania, USA
Division of Structural Biology, Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, England
Electron Bio-Imaging Centre, Diamond Light Source, Harwell Science and Innovation Campus, Didcot, United Kingdom

ABSTRACT  Human immunodeficiency virus type 1 (HIV-1) capsid binds host proteins during infection, including cleavage and polyadenylation specificity factor 6 (CPSF6) and cyclophilin A (CypA). We observe that HIV-1 infection induces higher-order CPSF6 formation, and capsid-CPSF6 complexes cotraﬃck on microtubules. CPSF6-capsid complex trafﬁcking is impacted by capsid alterations that reduce CPSF6 binding or by excess cytoplasmic CPSF6 expression, both of which are associated with decreased HIV-1 infection. Higher-order CPSF6 complexes bind and disrupt HIV-1 capsid assemblies in vitro. Disruption of HIV-1 capsid binding to CypA leads to increased CPSF6 binding and altered capsid trafﬁcking, resulting in reduced infectivity. Our data reveal an interplay between CPSF6 and CypA that is important for cytoplasmic capsid trafﬁcking and HIV-1 infection. We propose that CypA prevents HIV-1 capsid from prematurely engaging cytoplasmic CPSF6 and that differences in CypA cellular localization and innate immunity may explain variations in HIV-1 capsid trafﬁcking and uncoating in CD4+ T cells and macrophages.

IMPORTANCE HIV is the causative agent of AIDS, which has no cure. The protein shell that encases the viral genome, the capsid, is critical for HIV replication in cells at multiple steps. HIV capsid has been shown to interact with multiple cell proteins during movement to the cell nucleus in a poorly understood process that may diﬀer during infection of diﬀerent cell types. In this study, we show that premature or too much binding of one human protein, cleavage and polyadenylation speciﬁcity factor 6 (CPSF6), disrupts the ability of the capsid to deliver the viral genome to the cell nucleus. Another human protein, cyclophilin A (CypA), can shield HIV capsid from premature binding to CPSF6, which can diﬀer in CD4+ T cells and macrophages. Better understanding of how HIV infects cells will allow better drugs to prevent or inhibit infection and pathogenesis.

KEYWORDS CPSF6, capsid, cyclophilin A, human immunodeﬁciency virus, live-cell imaging, microtubule

H uman immunodeﬁciency virus type 1 (HIV-1) capsid is a unique structure that assembles after viral proteolytic cleavage of the Gag and Gag-Pol polyproteins during or after virus budding and release from cells. Multiple HIV-1 capsid proteins (CAs) form a conical-shaped core consisting of approximately 200 hexamers and 12
pentamers, which encapsulates two copies of the RNA genome (1, 2). An important yet understudied aspect of HIV-1 infection, which is referred to as uncoating, describes the process of capsid dissociation that occurs during reverse transcription and before viral DNA integration into host chromatin (3, 4). HIV-1 capsid uncoating is dependent on microtubule trafficking (5–7) and may occur in a multistep process (8). HIV-1 infection requires active transport of the viral reverse transcription complex/preintegration complex (RTC/PIC) through the cellular nuclear pore complex (NPC) (9), and the majority of capsid is likely uncoated at the NPC and/or within the nucleus (10–14). Single mutations in CA can greatly impact the stability of HIV-1 capsid, altering its uncoating and affecting virus infectivity (15, 16).

HIV-1 capsid has been shown to bind several host proteins during infection (17). Two examples are cyclophilin A (CypA) (18, 19), which is relatively abundant in cells (20), and cleavage and polyadenylation specificity factor 6 (CPSF6) (21). Disruption of HIV-1 capsid binding to CypA can occur via amino acid substitution, such as G89V and P90A, in the loop between helices 4 and 5 in CA (22, 23) or by treatment with small-molecule inhibitors, such as cyclosporine A (CsA) (18). The inability to bind to CypA in target cells can affect the infectivity of the invading HIV-1 particle (24). CypA dependence is cell type specific and has been shown to affect multiple steps in the virus life cycle, including capsid uncoating, reverse transcription, nuclear import, integration, and evasion of TRIM5α restriction (25–30).

CPSF6 is an arginine-serine (RS) domain-containing protein expressed predominantly in the cell nucleus and is involved in splicing and polyadenylation of host RNAs (31). CPSF6 binds to HIV-1 capsid at an interface between two CA monomers defined by helices 3, 4, and 5 (21, 32). The beta-karyopherin transportin 3 (TNPO3) is the key mediator of RS domain protein nucleocytoplasmic transport in cells, and TNPO3 directly binds the C-terminal RS domain in CPSF6 to affect its nuclear import (33, 34). Accordingly, truncation of the C terminus of CPSF6 leads to increased cytoplasmic expression and inhibition of HIV-1 nuclear entry and infection (21, 33) in a TNPO3-dependent manner (35, 36). Disruption of CPSF6 binding to HIV-1 capsid is mediated by alteration of CPSF6 at amino acid F321 in the central proline-rich domain (37) or by mutations in CA, including residues 57, 70, 74, 77, and 105 (21, 32, 38, 39). While reduction of CPSF6 expression or loss of capsid binding to CPSF6 in cells does not affect overall HIV-1 infection in most cell types, viral DNA integration is mistargeted outside gene-dense, transcriptionally active host chromatin to heterochromatic lamina-associated domains (28, 40, 41).

In this study, we investigated whether HIV-1 capsid interacts with CPSF6 in the host cell cytoplasm and whether this interaction affects capsid trafficking and subsequent virus infectivity in different cell types. Using live-cell microscopy, we visualized wild-type (WT) HIV-1 complexes colocalized with cytoplasmic CPSF6 that trafficked together on microtubules. By negative-stain transmission electron microscopy (TEM), we show that purified CPSF6 protein forms oligomers that bind and disrupt CA tubular assemblies. Inhibiting HIV-1 capsid interaction with CypA led to increased association of viral particles or in vitro CA assemblies with CPSF6 and changes in WT HIV-1 complex trafficking that corresponded to reduced infectivity. Depletion of CPSF6 affected capsid trafficking, albeit differentially depending on the cell type.

RESULTS

CPSF6 is expressed in the perinuclear region and traffics on microtubules with WT HIV-1 complexes. As CA protein may dissociate from HIV-1 nucleic acid complexes prior to entry into the nucleus where CPSF6 predominantly is expressed, we examined whether CPSF6 was expressed in the cell cytoplasm. Antibody staining of endogenous CPSF6 (NBP1-85676; Novus) or expression of green fluorescent protein (GFP)-tagged CPSF6 (CPSF6-GFP) in HeLa cells showed mostly nuclear expression as well as punctate cytoplasmic expression mainly near the nuclear membrane, which may indicate higher-order complex formation (Fig. 1A). Highly inclined and laminated optical sheet (HILO) live-cell microscopy enabled precise tracking of rapidly moving fluorescent proteins.
complexes at high temporal resolution with relatively low photobleaching. Perinuclear CPSF6-GFP puncta were shown to be dynamic in cells with linear movement and were colocalized with microtubules (Fig. 1B, Movie S1). Inhibition of microtubule polymerization with nocodazole inhibited CPSF6-GFP movement in cells, suggesting that CPSF6 traffics on microtubules itself or by binding another host protein (Fig. 1C).

As HIV-1 RTCs also traffic on microtubules (42) (Movie S2), we examined the association of fluorescently labeled HIV-1 particles with cytoplasmic CPSF6-GFP in cells. Vesicular stomatitis virus glycoprotein (VSV-G)-pseudotyped WT or N74D HIV-1 encoding firefly luciferase and labeled with integrase (IN) tagged with the fluorophore mRuby3 or tagRFP was used at equal amounts (10 ng p24) to infect cells expressing CPSF6-GFP. Labeled IN colocalized with viral RNA in particles or with viral RNA and CA
protein early after infection, the latter of which demarcates RTCs/PICs (43). WT complexes were colocalized with perinuclear CPSF6-GFP in HeLa cells, while N74D complexes were not (Fig. 2A). WT HIV-1 complexes were also colocalized with endogenous cytoplasmic CPSF6 in SupT1 CD4+ T cells (Fig. 2B). Multiple WT or N74D virus particles that colocalized with CPSF6-GFP were assessed by live-cell imaging over time. The fluorescence intensity of WT HIV-1 complexes remained associated with CPSF6-GFP, whereas the fluorescence intensity of N74D viral particles did not (Fig. 2C). This is consistent with a recent study showing WT HIV-1 particles associated with CPSF6 initially outside the nucleus (14). WT HIV-1 particles associated with CPSF6-GFP trafficked rapidly and linearly, suggestive of microtubule movement (Fig. 2D, Movie S3). Consistent with this interpretation, trafficking of WT HIV-1 particles associated with CPSF6-GFP was inhibited with nocodazole treatment (Fig. 2E). Finally, CPSF6 tagged with iRFP670 trafficked toward the nucleus with its TNPO3 binding partner, which was tagged with GFP (Fig. 2F, Movie S4). These results suggest that HIV-1 complexes traffic with CPSF6 on microtubules.

Changes in the CPSF6 RS domain alter WT HIV-1 complex trafficking. Truncation of CPSF6 at residue 358 (CPSF6-358), which removes the RS domain, or alteration of four positively charged amino acids (K547, R549, R559, and R561) in the RS domain to glutamic acid (CPSF6-4Glu) (Fig. 3A) leads to decreased nuclear localization of CPSF6 and restriction of WT HIV-1 infection at the step of nuclear entry (21, 33). Expression of iRFP670-tagged CPSF6-4Glu or CPSF6-358 led to increased cytoplasmic localization in cells, with the truncated protein showing a greater effect than the 4Glu mutant, which revealed greater variability in cytoplasmic expression levels than the other constructs (Fig. 3B). Similarly, expression of CPSF6-358 resulted in greater restriction of WT HIV-1 infection than expression of CPSF6-4Glu (Fig. 3C). N74D HIV-1, which does not bind to CPSF6, was not restricted by either mutant.

To determine if relocalization of CPSF6 to the cytoplasm affects HIV-1 complex trafficking, live-cell imaging of WT and N74D HIV-1 complexes was performed in cells expressing fluorescently tagged CPSF6, CPSF6-4Glu, or CPSF6-358. To avoid imaging particles that have not yet fused out of endosomes into the cytoplasm, imaging was performed using mRuby3-IN-labeled WT HIV-1 particles that were also labeled with the glycosylphosphatidylinositol targeting motif of decay-accelerating factor (44) tagged with fluorogen-activating protein (FAP-GPI) to label the virus membrane. Loss of FAP-GPI signal from the mRuby3 signal signified that the HIV-1 membrane had fused with the endosome and the contents of the virus were released into the cytoplasm. During synchronized infection, we observed that nearly all mRuby3 signal separated from the viral membrane by 50 min (data not shown). Thus, for virus tracking experiments, acquisition of images began at 60 min postinfection.

Fluorescent IN complexes were analyzed for average speed, track length (distance), and track straightness (calculated by the distance between the end points over the trajectory length; also known as displacement). In HeLa cells expressing CPSF6-GFP, WT and N74D viral complexes had similar speeds and track lengths but differed in track straightness (Fig. 3D, Fig. S1), suggesting that both capsids utilize microtubules but differences in binding host proteins affect microtubule movement. WT HIV-1 particle movement in cells expressing CPSF6-GFP did not differ from normal HeLa cells (data not shown). In contrast, WT HIV-1 particles increased in all three measurements when CPSF6-4Glu-iRFP670 or CPSF6-358-iRFP670 was expressed in cells (Fig. 3D, Fig. S1). Little or no change in particle speed, track length, or track straightness was observed for N74D complexes in the presence of CPSF6-4Glu or CPSF6-358. Similar to the effect of increased CPSF6 cytoplasmic localization on WT HIV-1 infectivity, average WT virus particle speed and track length inversely correlated with the intensity of nuclear CPSF6 expression (Fig. 3E). These data suggest that HIV-1 complex trafficking is altered in the cytoplasm by enhanced CPSF6 cytoplasmic localization. Furthermore, increased HIV-1 mobility is associated with an infectivity defect.

CPSF6 oligomerizes and disrupts assembled WT CA. Previously, we showed that purified recombinant CPSF6-358 protein formed oligomers and disrupted WT HIV-1 CA.
FIG 2  HIV-1 complexes associate with perinuclear CPSF6 and cotraffic on microtubules. (A) Confocal images of HeLa cells \((7.5 \times 10^5)\) expressing CPSF6-GFP (green) are shown 60 min after infection with 10 ng p24 equivalent of WT HIV-1 or N74D HIV-1 containing (Continued on next page)
tubular assemblies in vitro (43). To determine whether full-length CPSF6 had similar properties, it was purified and characterized with WT and N74D CA tubular assemblies. To obtain soluble CPSF6, an N-terminal maltose binding protein (MBP) fusion construct was expressed and purified, resulting in two peaks in size exclusion chromatography (Fig. S2A, labeled P1 and P2) that corresponded to the tagged full-length CPSF6, as confirmed by Western blot analysis (Fig. S2B). This suggests that the purified fusion protein may adopt different oligomeric states similar to what was observed for CPSF6-358, which also displayed two peaks in a size exclusion chromatography profile with dimer and large oligomers (43). Removal of the MBP-tag with HRV-3C protease resulted in precipitation of CPSF6 from both P1 and P2 (Fig. S2C). Therefore, MBP-tagged soluble MBP-His6-CPSF6-588 (denoted here as “MBP-CPSF6”) was used for further binding experiments.

Incubation of in vitro preassembled WT HIV-1 CA tubes with MBP-CPSF6 (both P1 and P2) resulted in cosedimentation of MBP-CPSF6/CA complexes in the pelleted fractions (Fig. 4A). The ratio of CPSF6 to WT CA in the pelleted fraction was 0.097 ± 0.005. Negligible binding of MBP-CPSF6 to N74D HIV-1 CA tubes was observed under the same assay conditions, giving a CPSF6/CA ratio of 0.006 ± 0.008. TEM of the negative stained samples showed a drastic structural disruption of capsid tubes when incubated with MBP-CPSF6 (P1 or P2), while N74D CA tubes remained intact (Fig. 4C). MBP-CPSF6, by itself, formed protein oligomers for both P1 and P2 fractions in CA assembly buffer (Fig. 4B). Binding of MBP-CPSF6 to WT CA tubes resulted in dissolution of tubes and an appearance of distinct curved capsid remnants associated with MBP-CPSF6 densities. Intriguingly, the amount of pelletable capsid did not change upon capsid disruption (Fig. 4A), suggesting that the predominant effect of MBP-CPSF6 is HIV-1 capsid fragmentation without dissociation into soluble proteins. Dose-dependent binding of MBP-CPSF6 to CA tubes was observed for both MBP-CPSF6 P1 and P2 by TEM (Fig. S3). This represents the first direct evidence of full-length CPSF6 binding to and disruption of WT CA tube assemblies.

HIV-1 induces cytoplasmic higher-order CPSF6 complex formation in a CypA-dependent manner. In cells, CPSF6-358 forms puncta around WT HIV-1 mRuby3-IN complexes early after virus entry, leading to premature capsid permeabilization (43). These did not form in the presence of a small-molecule inhibitor, PF74, which blocks CPSF6 binding to capsid (45), or if N74D HIV-1 was used. To determine if full-length higher-order CPSF6 complexes form in the cytoplasm, immunostaining of CPSF6 was performed before and after HIV-1 infection. Higher-order CPSF6 complexes were visualized in the perinuclear region after WT HIV-1 infection but not after N74D HIV-1 infection (Fig. 5A and B) and were associated with IN-containing complexes (Fig. 2) and CA (p24) staining (Fig. 5A). CPSF6 puncta were also observed in the nuclei of cells at later time points after WT HIV-1 infection (data not shown). Consistent with our in vitro results (Fig. 4), these data suggest that CPSF6 binds to WT capsid in the cytoplasm of infected cells.

Our previous work demonstrated that higher-order CPSF6-358 complexes were larger and formed more rapidly when CypA binding to CA was inhibited by CsA (43).
Therefore, we examined whether the same would be true for full-length CPSF6. Indeed, when cells were treated with CsA and infected with WT HIV-1, greater numbers of CPSF6 higher-order complexes were observed (Fig. 5A and B). The volume of the complexes that formed in the presence of WT virus increased with increasing

FIG 3 Alteration of the CPSF6 RS domain impacts HIV-1 trafficking. (A) CPSF6 protein domains and associated CPSF6-4Glu and CPSF6-358 changes. (B) Confocal microscopy images are shown of cells expressing CPSF6-iRFP, CPSF6-4Glu-iRFP, or CPSF6-358-iRFP. Cell peripheries are indicated by dotted lines. The graph shows the nuclear to cytoplasmic ratio of CPSF6 for each construct (n = 25). (C) Infection of WT and N74D HIV-1 in HeLa cells expressing iRFP, CPSF6-iRFP, CPSF6-4Glu-iRFP, or CPSF6-358-iRFP is shown as luciferase expression (counts per second, or cps) from 2 representative independent experiments. Error bars indicate the STDEV of duplicates. (D) The average particle speeds, track lengths, and track straightness of WT or N74D HIV-1 mRuby3-IN complexes in HeLa cells expressing CPSF6-iRFP, CPSF6-4Glu-iRFP, or CPSF6-358-iRFP are shown from one of two independent HILO live-cell imaging experiments (see also Fig. S1). Error bars indicate the SEM. (E) Correlations of the average particle speed or average track length and CPSF6 nuclear:cytoplasmic ratio are shown for WT and N74D HIV-1.
concentrations of CsA (Fig. 5C), suggesting that inhibiting more CypA binding allowed more CPSF6 to bind to HIV-1 capsid. In contrast, CPSF6 complex formation was indistinguishable from background after infection with N74D HIV-1 (Fig. 5A and B). To confirm that the loss of CypA binding to capsid was responsible for the increase in CPSF6 higher-order complexes, cells were infected with HIV-1 CA mutant G89V, which is defective for CypA binding (23). Because G89V HIV-1 is restricted by CPSF6-358 and thus can still bind CPSF6 (35), we expected that this virus would induce CPSF6-GFP puncta that would not increase in number in the presence of CsA, which is what was observed (Fig. 5B).

**FIG 4** CPSF6 binds to and disrupts CA tubular assemblies. (A) SDS-PAGE analysis of WT and N74D CA assemblies following incubation with MBP-CPSF6 P1 or P2 and centrifugation. The gel was stained with Coomassie blue; supernatant (s) and pellet (p) samples are indicated. (B) Representative negative-stain EM micrographs are shown of P1 or P2 incubated in buffer. (C) Representative negative-stain EM micrographs are shown of WT CA (top panels; see also Fig. S3) and CA N74D (bottom panels) tubular assemblies alone (control) or with 9 μM MBP-CPSF6 P1 or P2. The arrows indicate capsid fragments. Scale bar, 100 nm.
FIG 5  HIV-1 induction of cytoplasmic CPSF6 higher-order complex formation as a function of CypA binding. (A) Representative confocal micrographs are shown of HeLa cells stained with CPSF6 antibodies (green) and Hoechst (blue) after infection with WT HIV-1 and WT or N74D HIV-1 in the presence of 10 μM CsA. Viruses contain mRuby3-IN (red). (B) Cytoplasmic CPSF6 staining was quantified in cells (n=1,235) treated with or without 10 μM CsA and infected for 1 h with WT, N74D, or G89V HIV-1. (C) The average volume of cytoplasmic CPSF6 puncta (n=1,235) was quantified in HeLa cells treated with or without CsA. Cells expressing CPSF6-358-GFP were used as a positive control. (D) CA-NC assemblies were incubated for 1 h in buffer, with CypA-DsRed, or CypA-DsRed and CsA, and then incubated with MBP-CPSF6 P1 or P2 for 1 h. The relative binding of CPSF6 binding to CA-NC assemblies was quantified in each sample from stained SDS-PAGE gels. Error bars indicate the STDEV from 3 independent experiments. (E) A representative confocal micrograph of HeLa cells stained with Hoechst (blue) and CypA antibodies (red). (F) The average particle speeds and track lengths of WT, N74D, or G89V HIV-1 mRuby3-IN complexes in HeLa cells treated with or without 10 μM CsA are shown for 1 of 3 independent experiments with 719 to 5,009 particles per condition. Error bars indicate the SEM.
As removal of CypA from HIV-1 capsid enhanced CPSF6 higher-order complex formation, we hypothesized that CPSF6 complex formation may be prevented if CypA binding to capsid was enhanced. Thus, virus was produced in the presence of CypA-DsRed, an oligomeric form of fluorescently labeled CypA with higher avidity to HIV-1 capsid than unlabeled CypA (46). Cells were infected with WT HIV-1 labeled with CypA-DsRed or with mRuby3-IN in the presence or absence of CsA and stained for CA (p24; Fig. S4B). Similar levels of p24 staining were observed under all conditions. Virus containing mRuby3-IN led to formation of many CPSF6-358-GFP puncta associated with p24 that increased with CsA treatment (Fig. S4A). However, cells infected with CypA-DsRed-labeled HIV-1 had significantly fewer GFP puncta, and CsA treatment did not increase their formation, suggesting that enhanced CypA binding to capsid prevents HIV-1 interaction with CPSF6-358 and, likely, also CPSF6.

To directly test the ability of CypA to shield CPSF6 binding to HIV-1 capsid, MBP-CPSF6 protein (P1 and P2) binding to nanotubes composed of recombinant WT CA-SP1-nucleocapsid (CA-NC) protein was quantified in the presence or absence of CypA-DsRed and in the presence or absence of CsA (Fig. S4C). Binding of CypA-DsRed to CA-NC tubes was not affected by subsequent MBP-CPSF6 binding but was inhibited by CsA treatment (Fig. S4D). MBP-CPSF6 binding to HIV-1 CA-NC tubes decreased when CypA-DsRed was already bound, effects that were rescued partially (P1) or completely (P2) by the presence of CsA (Fig. 5D). Collectively, these data demonstrate that CypA binding to capsid prevents CPSF6 from binding.

Loss of CypA binding leads to altered cytoplasmic trafficking of WT HIV-1 complexes in a CPSF6-dependent manner. Although CypA is packaged into virions, HIV-1 capsid interactions with target cell CypA modulate infectivity (24). In contrast to CPSF6 expression, endogenous CypA localized to the cytoplasm of HeLa cells with somewhat of a filamentous appearance (Fig. 5E, Fig. S5A). Interestingly, not only was CypA excluded from the nucleus, but its expression was absent from portions of the perinuclear region (Fig. S5A) that corresponded to the microtubule-organizing center (Fig. S5B). Similar expression of CPSF6 and CypA was observed in SupT1 CD4+ T cells (Fig. S5C).

To determine whether the loss of CypA binding to HIV-1 capsid could affect virus trafficking, live-cell microscopy was performed on WT, N74D, and G89V HIV-1 in the presence and absence of CsA (data not shown). In the absence of drug, the average speed and track length of viral complexes were similar for WT HIV-1 and N74D HIV-1, while G89V HIV-1 complexes trafficked significantly faster and had similar track lengths. As observed for WT HIV-1 trafficking in cells expressing mutant CPSF6 (Fig. 5), the higher rate of speed of G89V viral complexes was associated with lower infectivity (Fig. 5D). However, CsA treatment led to significantly increased speed and track length of WT HIV-1 particles. CsA did not affect N74D or G89V viral particles. These results suggest that the loss of CypA binding to WT capsid influences trafficking of HIV-1 complexes in the cytoplasm in a CPSF6-dependent manner, as N74D viral particles were not affected by CsA treatment. G89V complexes that bind to CPSF6 but not CypA had altered trafficking and lower infectivity irrespective of CsA treatment. The expression and trafficking data together suggest that CypA prevents virus cores from binding prematurely to CPSF6 during trafficking to the nucleus.

Depletion of CPSF6 rescues the HIV-1 complex trafficking defect caused by loss of CypA binding. To validate that the effect of CsA treatment on WT viral complex trafficking is mediated by CPSF6, CPSF6 was depleted from cells using short hairpin RNA (shRNA) knockdown. HeLa cells were transduced with lentiviruses expressing a shRNA targeting CPSF6 or a scrambled control shRNA. Knockdown (KD) of CPSF6 was verified by immunofluorescence staining (Fig. 6A). In the absence of CsA, CPSF6 KD had no effect on WT virus particle tracking (Fig. 6B). Infectivity of WT HIV-1 in untreated cells decreased after CPSF6 depletion (Fig. 6C), which may be attributable to previously described reduced cell proliferation of CPSF6 knockout cells (40). As shown above
CsA led to a significant increase in WT HIV-1 complex speed and track length in HeLa cells (Fig. 6B). The CA mutants showed different cytoplasmic trafficking patterns compared to WT HIV-1. N74D complex trafficking was unaffected by CPSF6 KD and/or CsA treatment (Fig. 6B). Interestingly, depletion of CPSF6 led to a significant decrease in G89V HIV-1 complex trafficking with or without 10 μM CsA treatment, which corresponded to a rescue of the infectivity defect of this mutant (Fig. 6C). Our data indicate that CypA alters HIV-1 trafficking in a CPSF6-dependent manner, further suggesting that CypA binding protects HIV-1 capsid from binding too prematurely to or too much of CPSF6.

As the HeLa cell model may not fully recapitulate HIV-1 trafficking or infection in...
primary CD4+ T cells, infectivity of WT HIV-1 and CA mutants was performed in phytohemagglutinin (PHA)-stimulated primary human peripheral blood mononuclear cells (PBMC) from 3 donors. Cells were infected in the presence or absence of CPSF6 depletion and CsA treatment. Depletion of CPSF6 was verified by Western blot quantification (Fig. 6D, Fig. S6A). Similar to the HeLa cell data, infection of N74D and G89V HIV-1 was inhibited in primary PBMC (Fig. 6E, Fig. S6B), as previously reported (21, 47). Depletion of CPSF6 partially rescued G89V HIV-1 infectivity (Fig. 6E, Fig. S6B). Although the luciferase values were comparatively low for this mutant, the data reproducibly trended with what was observed in HeLa cells (Fig. 6C).

Depletion of CPSF6 in macrophages results in decreased HIV-1 infectivity independent of CypA binding. As we and others previously showed that N74D HIV-1 has an early infectivity defect in monocyte-derived macrophages (MDM) (28, 48), we investigated whether intracellular trafficking of HIV-1 is dependent on CPSF6 and CypA. MDM were stained for endogenous CypA and CPSF6 expression. As in HeLa cells, CPSF6 expression was predominantly nuclear in MDM (Fig. 7A). However, infection with WT HIV-1 failed to induce higher-order CPSF6 complex formation in the cytoplasm (data not shown), consistent with previous results (49) and indicative of less cytoplasmic CPSF6 expression in MDM than in HeLa cells. In contrast, CypA expression differed greatly between cell types. MDM had pronounced nuclear CypA expression in addition to patches of plasma membrane and cytoplasmic expression (Fig. 7B).

CPSF6 was depleted with shRNA in MDM, which was confirmed by immunostaining (Fig. 7A and C). Trafficking of mRuby3-IN complexes was evaluated in MDM from 3 donors with and without CPSF6 depletion. CPSF6 depletion led to a significant increase in speed and track length of WT HIV-1 complexes (Fig. 7D). Loss of CPSF6 led to a modest decrease in WT HIV-1 single-cycle infectivity, with only donor 2 being significant (Fig. 7E). However, CPSF6 depletion led to a significant decrease in spreading infection with WT HIV-1 but not with N74D HIV-1 in MDM (Fig. 7F). In normal MDM, both N74D and G89V HIV-1 had significantly decreased infectivity, which corresponded to faster mRuby3-IN trafficking (Fig. 7E). CPSF6 depletion had no effect on the trafficking of mutant CA complexes or subsequent infection. These results suggest that loss of CPSF6 in macrophages affects WT HIV-1 CA trafficking, leading to decreased infectivity.

CsA treatment of MDM significantly increased WT HIV-1 complex trafficking speed (Fig. 7G), with a corresponding decrease in infection in all donors (Fig. 7E). CPSF6 KD with CsA treatment (i.e., loss of CPSF6 and CypA binding) led to a significant increase in infectivity of WT virus in all donors compared to CsA treatment alone. N74D HIV-1 infection was significantly reduced during CsA treatment, with or without CPSF6 KD. Although the loss of CypA binding significantly reduces virus infectivity, these results suggest that alteration of HIV-1 trafficking and infectivity by depletion of CPSF6 is independent of CypA binding in macrophages.

**DISCUSSION**

HIV-1 capsid has been shown to interact with many host cell factors (17). Included in this list is CPSF6, which is involved in mRNA cleavage and polyadenylation in the nucleus (21). In this study, we detected cytoplasmic, punctate expression of endogenous or fluorescently tagged CPSF6 in the perinuclear region of cells. Full-length MBP-CPSF6 protein formed oligomers in vitro that bind to HIV-1 CA assemblies, similar to what we previously reported for CPSF6-358 (43), which lacks the RS domain but retains the central proline-rich domain that mediates CA binding. In cells, CPSF6 puncta likely represent higher-order complexes that bind to HIV-1 capsid in the cytoplasm after viral entry. This is consistent with a recent study in which examples of CPSF6 associated with HIV-1 complexes in the cytoplasm were shown prior to nuclear import (14). Removal or truncation of the CPSF6 RS domain leads to mislocalization of CPSF6 to the periphery of the cell due to loss of TNPO3 binding and reduced HIV-1 nuclear import and infectivity (21, 33, 35). Here, we demonstrate with live-cell imaging that HIV-1 complexes trafficked with CPSF6 in a capsid-dependent manner. In addition, virus complexes increased in speed in the presence of CPSF6 RS mutants or by introducing the
FIG 7 CPSF6 KD decreases HIV-1 infection in MDM. (A) Representative confocal micrographs are shown for CPSF6 antibody (white) and Hoechst (blue) staining in MDM without transduction or after transduction with lentiviruses expressing SCR shRNA or CPSF6 shRNA. The white bars indicate 5 μm. (B) A representative confocal micrograph of an MDM stained with Hoechst (blue) and CypA (red) is shown. (C) The mean intensity of CPSF6 antibody staining is shown from individual MDM transduced with lentiviruses expressing SCR or CPSF6 shRNA. Error bars indicate the STDEV of n = 77 cells. (D) The average particle speeds of WT, N74D, or G89V HIV-1 mRuby3-IN complexes in MDM from 1 of 3 individual donors treated with scrambled shRNA (SCR KD) or CPSF6 shRNA are shown. Error bars indicate the SEM. (E) The infection of WT, N74D, or G89V HIV-1 in the same cells as shown in panel B are graphed. Error bars indicate the STDEV of duplicates, and the dotted line represents the average luciferase expression of uninfected cells. (F) WT and N74D HIV-1 mRuby3-IN complexes in MDM from a representative donor treated with or without CsA are shown. Error bars indicate SEM.
CA N74D mutation that abolishes CPSF6 binding. Interestingly, increased microtubule trafficking of HIV-1 was associated with reduced infectivity. Previously, we showed significant colocalization of CPSF6-358 to mRuby3-IN complexes in the cytoplasm, likely due to a high concentration at the cell periphery that was not seen with full-length CPSF6 (43). It is possible that overall faster and longer trafficking is due to CPSF6-mediated modulation of capsid integrity, which may alter the accessibility of capsid to other host proteins, such as certain microtubule motor proteins or motor adaptors that can alter cargo trafficking speed, track length, and bidirectional transport (50).

Previously, it was shown that HIV-1 capsid traffics on microtubules on its way to the nucleus (42) and that CA binds key NPC component proteins (17). HIV-1 capsid uncoating is delayed by destabilization of microtubules or knockdown of the microtubule motor proteins kinesin and dynein (5, 6), suggesting that microtubule trafficking and NPC binding are linked to capsid uncoating. Here, we demonstrate that HIV-1 capsid trafficked with CPSF6 and TNPO3 on microtubules and that CPSF6 facilitated CA tubular disassembly. Our previous work demonstrated that CPSF6-358 associates with HIV-1 complexes in a CA-dependent manner and leads to more rapid uncoating kinetics and reduced virus infectivity (43). Therefore, CPSF6 may play a role in both HIV-1 capsid uncoating, which may initiate in the cytoplasm, and nuclear import (49, 51).

CypA binding to HIV-1 capsid was described nearly 3 decades ago (18), yet until recently, its role in HIV-1 infection was ill defined. Here, we show that the loss of CypA binding to HIV-1 capsid in infected cells due to CsA treatment coincided with increased capsid binding to CPSF6, which is consistent with our previous results with fluorescently labeled CPSF6-358 (43). Conversely, production of HIV-1 in the presence of CypA-DsRed, which has increased binding to capsid compared to untagged CypA (46), reduced CPSF6 binding to capsid. This was also seen in vitro in a competitive binding assay with CA-NC assemblies in the presence of CypA-DsRed and MBP-CPSF6 proteins. Trafficking of HIV-1 complexes in cells increased in the presence of CsA or with the G89V CA mutation, which correlated with decreased infectivity. These results suggest that CypA binding to capsid prevents CPSF6 binding. As CypA expression in HeLa cells was restricted to the cell periphery, from which CPSF6 was excluded, we hypothesize that CypA interacts with HIV-1 capsid in the cell periphery first to prevent CPSF6 binding to HIV-1 capsid before the perinuclear region, ensuring that uncoating does not occur prematurely (Fig. 8).

Depletion of CPSF6 in cells did not affect HIV-1 infection in HeLa cells or PBMC, as previously demonstrated (21), nor did it alter HIV-1 trafficking to the nucleus in HeLa cells. As N74D HIV-1 was associated with microtubules and trafficked in a linear fashion like WT HIV-1, we suggest that HIV-1 microtubule trafficking and nuclear import can be independent of CPSF6. Surprisingly, the loss of CPSF6 expression affected WT and G89V HIV-1 trafficking during CsA treatment but did not affect N74D HIV-1 trafficking. Alterations in HeLa trafficking under these conditions corresponded with HeLa infectivity data. These results again highlight the interplay of CPSF6 and CypA in capsid interaction. As it has not been possible to knockout CPSF6 or completely deplete CPSF6 from these cells, these data further suggest that the loss of CypA binding allows more CPSF6 binding to occur outside the nucleus, which affects trafficking and infectivity.

Although high-speed imaging of HIV-1 particles in CD4+ T cells was not possible, infection results after CPSF6 depletion and/or CsA treatment in primary PBMC largely mimicked those seen in HeLa cells. In addition, expression of CPSF6 and CypA are similar in CD4+ T cells and HeLa cells. However, CsA treatment significantly reduced the infectivity of WT HIV-1 as well as the CA mutants. Recent studies revealed that the loss of CypA binding, by either depletion, CsA treatment, or CA mutations, led to significant restriction of HIV-1 infection by human TRIM5α in CD4+ T cells (30, 52). Similarly, we show that trafficking of G89V HIV-1 complexes or WT HIV-1 in the presence of CsA was aberrant in MDM, which corresponded with reduced infectivity. As in CD4+ T cells, the loss of CypA binding to HIV-1 capsid in macrophages led to human TRIM5α restriction prior to completion of reverse transcription (29). Furthermore, N74D HIV-1 is restricted...
in macrophages and CD4+ T cells by TRIM34 in a TRIM5α-dependent and CPSF6-independent manner (52). Thus, CypA binding to HIV-1 capsid may be protective against multiple capsid-binding cellular factors. Further structural studies will be needed to understand the interplay of CypA, CPSF6, and TRIM5α/TRIM34 binding to WT and mutant HIV-1 capsids.

While some CA may be lost from the capsid in the cytoplasm, CA is required for docking at NPCs and for nuclear entry (11, 12, 53). Recent work from several groups has shown that capsid uncoating and reverse transcription are completed inside the nucleus in multiple cell types (14, 54, 55). However, some differences have been observed in different cell types. For example, imaging of HIV-1 capsids showed they were more stable in the cytoplasm of MDM than HeLa-derived cells (56). Similarly, most CA staining was lost from HIV-1 complexes in the nucleus of HeLa cells, while more viral complexes were CA positive in MDM (51, 56, 57) and colocalized with CPSF6 puncta (49, 55). Here, we show that CypA localized to both the cytoplasm and nucleus in MDM, whereas it was only expressed in the periphery of the cell in HeLa cells. Thus, HIV-1 capsid may be shielded from CPSF6 and other host factors by CypA for longer periods of time in MDM (Fig. 8). Also, little to no cytoplasmic CPSF6 puncta are detected in MDM. As we showed that CPSF6 binding to capsid was prevented by CypA binding and promoted capsid dissociation, CypA expression in the perinuclear region and nucleus of MDM could explain why more CA remains associated with the viral genome in these cells compared to HeLa cells. Our results contribute to the growing literature on the ability of HIV-1 capsid to bind multiple host cell factors in a highly orchestrated manner to promote viral infectivity, which differs depending on the specific cellular environment.

MATERIALS AND METHODS

Plasmids. The replication-defective HIV-1 proviral plasmid pNLdE-luc has been described (21, 48). Viruses were pseudotyped with pL-VSV-G (58). N74D was also introduced similarly in a replication-competent proviral plasmid, pNL4-8AL (gift from Ned Landau). pVpr-mRuby3-IN was previously described (43), and a similar version, pVpr-tagRFP-IN was also used.
Lentiviral vectors were used to introduce tagged host proteins or shRNA to cells. Fluorescently tagged CPS6 and related mutants were introduced into the pSICO vector using the BamHI and NotI sites. pSICO-GFP-TNPO3 was created using same sites with GFP-TNPO3 (gift from Ned Landau). pLenti-FAP-GPI was created using the BamHI and NotI sites to move the FAP-GPI sequence from pcDNA-IgKappa-myc-dLS-2XG45-GPI (Addgene; catalog no. 153308) into pLenti-puro (gift from Le-Ming Shih; Addgene; catalog no. 39481). A plasmid encoding CyaA-DsRed (46) was a gift from Greg Melikyan. The lentiviral vector pHiVSiren expressing CPS6 shRNA (59) was a gift from Greg Towers. pLKO.1-puro-shNT (gift from Jacob Corn; Addgene; catalog no. 109012) was used as a scrambled shRNA control. The lentiviral packaging plasmid pSPAX2 (gift from Didier Trono; Addgene; catalog no. 109012) and pCMV- VSV-G were used to produce viruses.

The CPS6 gene and the MBP tag were amplified by PCR and subcloned into the pcDNA3.1(+) mammalian expression vector (Thermo Fisher Scientific) using the NEBuilder HiFi assembly kit (New England Biolabs) after linearization with the restriction enzymes EcoRI and XbaI. The resulting insert, designated MBP-6His6-CPS6-588, has a leading Kozak sequence, an N-terminal MBP tag, followed by a hexahistidine tag (His6).

HIV-1 CA and CA-NC were previously described (60, 61). In brief, they were cloned from the DNA of PBSS 

which was obtained from the NIH AIDS Research and Reference Reagent Program, Division of AIDS, NIAID, NIH. Briefly, CA and CA-NC regions were amplified and subcloned into pET21 (EMD Chemicals, Inc.) using the Ndel and Xhol sites. Proteins were expressed and purified as previously described for Gag (ΔMA15-103Δp6) (2, 62). CyaA-DsRed-Exp2 (gift from Greg Melikyan) was cloned into the pET28 vector, resulting in an N-terminal His6-tagged protein.

Cells. HeLa and HEK 293T cell lines were cultured in Dulbecco’s modified Eagle medium (DMEM; Thermo Fisher Scientific) supplemented with 10% fetal bovine serum (FBS; Atlanta Biologicals), 100 U/ml penicillin, 100 μg/ml streptomycin, and 2 mM l-glutamine (PSG; Thermo Fisher Scientific) at 37°C and 5% CO2. Stable cell lines were made by transduction with lentiviruses expressing fluorescently tagged host proteins following fluorescence-activated cell sorting. GHOST-R3/X4/RS lentiviral reporter cells (63) were cultured in DMEM supplemented 10% FBS, PSG, 100 μg/ml Geneticin G418 (Thermo Fisher Scientific), 0.5 μg/ml puromycin (Invitrogen), and 100 μg/ml hygromycin B (Invitrogen). SupT1 cells were cultured in RPMI 1640 medium (Thermo Fisher Scientific) supplemented with 10% FBS and PSG at 37°C and 5% CO2.

Human PBMCs were isolated from leukapheresis obtained from the Central Blood Bank (Pittsburgh, PA) using Ficol-Paque Plus (GE Healthcare) density gradient centrifugation following the manufacturer’s instructions. PBMCs were cultured in RPMI 1640 medium supplemented with 10% FBS, PSG, and 20 U/ml recombinant IL-2 (Thermo Fisher Scientific) at 37°C and 5% CO2. To expand T lymphocytes, PBMCs were stimulated with 50 U/ml IL-2 and 2 μg/ml phytohemagglutinin (PHA; Sigma-Aldrich) for 72 h prior to infection or transduction. CD14+ monocytes were isolated from PBMCs using human anti-CD14 magnetic beads with LS columns (Miltenyi Biotec). CD14+ monocytes were differentiated into MDM in RPMI 1640 medium supplemented with 10% FBS, PSG, and 50 ng/ml recombinant granulocyte-macrophage colony-stimulating factor (R&D Systems) for 7 days at 37°C and 5% CO2, prior to experimentation.

Viruses. Replication-defective HIV-1Δ3,4,5-luciferase virus pseudotyped with VSV-G was produced by transfection of HEK 293T cells or HEK 293T cells stably expressing FAP-GPI with pNLDe1-uc, pL-VSV-G, and pVpr-pcs-mRuby3-3N-pVpr-tagRFP-IFN/CyaA-DsRed at a weight ratio of 5:5:1. Replication-competent HIV-1 was produced by transfection of HEK 293T cells with the full-length proviral construct. Lentiviruses encoding fluorescent host proteins were produced by transfecting HEK 293T cells with lentiviral packaging, and pCMV-VSV-G plasmids at a weight ratio of 4:3:1. Transfections were performed using Lipofectamine 2000 (Invitrogen). Viruses were filtered through a 0.45-μm filters, concentrated with Lenti-X (Takara Bio) following the manufacturer’s protocol, and stored at –80°C. Viruses were quantified by p24 enzyme-linked immunosorbent assay (ELISA) (XpressBio) and the titer was determined on GHOST-R3/X4/RS cells. FAP-GPI, mRuby3-3N, and CyaA-DsRed labeled viruses were assessed for labeling efficiency by total internal reflection fluorescence (TIRF) imaging.

HIV-1 infection assays. HeLa cells and differentiated macrophages were seeded in 24-well plates overnight and then transduced with shRNA-encoding viruses. Next, 48 h posttransduction, cells were infected with equal p24 amounts of luciferase reporter viruses for 48 h. Cells were lysed and assessed for luciferase production (Promega) with a 1450 MicroBeta TriLux microplate luminometer (PerkinElmer). CPS6-KD efficiency was assessed by CPS6 antibody staining (NB1-85676). PHA-stimulated PBMCs were transduced with viruses encoding shRNA and selected with 2 μg/ml puromycin for 72 h. KD efficiency was measured by Western blot analysis. PBMCs were restimulated with PHA and challenged with luciferase reporter viruses for 72 h prior to luciferase measurement. For assays including treatment with CsA, cells were treated with CsA (10 μM) at the time of plating and remained in drug-containing medium throughout the assay.

Replication of HIV-1 in macrophages was performed in duplicate by infecting transduced macrophages with WT or N74D HIV-1Δ3,4,5,6,8 at a multiplicity of infection of 0.1. Supernatant was collected and new medium was added every 2 days. Viral replication was quantified by p24 production in the supernatant by ELISA (XpressBio) at day 8.

Fluorescence microscopy. For fixed HeLa cell or macrophage imaging, cells were plated in MatTek dishes overnight. Synchronized infections with VSV-G pseudotyped HIV-1 were performed by incubation at 4°C for 10 min, followed by aspiration of medium, addition of cold fluorescently labeled HIV-1 (5 ng p24), and further incubation at 4°C for 15 min to allow virus attachment. Cells were then incubated at 37°C for 20 min, followed by washing with warm medium and incubation in fresh medium. At 1 h postinfection, cells were washed with phosphate-buffered saline (PBS), pH 7.4, and fixed with 2%
parafomaldehyde (PFA). For SupT1 cell imaging, cells were infected in 6-well plates at room temperature with 10 ng p24 equivalent of virus per million cells for 30 min and then at 37°C for 3.5 h. Cells were centrifuged and washed twice with PBS and fixed with 2% PFA for 15 min. MatTek dishes were pre-coated with Cell-Tak (Corning) following the manufacturer’s instructions at least 2 h before seeding SupT1 cells. After permeabilization with 0.1% TritonX-100 for 15 min, fixed samples were blocked with serum matching the secondary antibody for 45 min. Primary antibodies were added to the fixed cells in protein binding buffer (PBB) (2% bovine serum albumin in PBS) for 1 h and washed with PBB. Secondary antibodies were added to the cells in PBB for 1 h. After washing with PBB and PBS, the cells were stained with Hoechst (1:2,000) and mounted with a coverslip using gelvetol.

A Nikon A1 confocal microscope was used to acquire three-dimensional (3D) stack images of fixed samples with a 100 × 1.49 NA oil-immersion objective. LU-NV laser launch (Nikon) was used to emit lasers at 405 nm, 488 nm, 561 nm, and 640 nm. Fields of view were randomly chosen by quick scanning in the Hoescht channel. The ND Acquisition option in NIS-Elements software (Nikon) was applied to collect 3D multichannel imaging (1,024 by 1,024 pixels) with 2× line averaging. Images of 488-nm and 561-nm channels were acquired by gallium arsenide phosphate (GaAsP) detectors (Nikon). 3D stacks were acquired with 0.15- to 0.5-μm step intervals to cover the entire cell volume (6 to 10 μm) with a motorized piezo Z stage (Nikon).

For live-cell HILO imaging, a Nikon Ti TIRF microscope with a 100 × 1.49 NA oil-immersion objective and a Photometrics Prime 95B sCMOS camera was used. In multicolor live-cell imaging experiments, a Flight Lakes Instrumentation high speed filter wheel was used. Synchronized infections in HeLa cells or macrophages were performed as described above. After shifting to 37°C for 20 min, cells were washed with prewarmed fresh medium—FluoroBrite medium (Thermo Fisher Scientific) for HeLa cells or RPMI 1640 medium for macrophages. After 1 h postinfection, the MatTek dish was loaded on the stage insert and maintained at 37°C (Tokai Hit stage chamber). Each image was acquired at least 1 frame per second (FPS) to track viruses for 10 min. For visualizing microtubules, 1 μM SIR-tubulin (Cytoskeleton) was added to the medium 30 min prior to imaging. For visualizing viral membranes, the MG-B-Tau FAP dye (64) was added to the virus at 500 nM for 10 min prior to addition to cells. RAM capture in Nikon Elements was used to achieve faster multicolor live-cell imaging (≥2 FPS).

**Imaging quantification and data analysis.** All imaging quantification was performed with General Analysis 3 in Nikon Elements (5.20.00 or above). Briefly, a cell nuclei binary mask was created using Hoechst signal to calculate the number of cells in each field of view. CPSF6 localization and quantification were determined by creating binary masks of CPSF6 within the cells. Cytoplasmic CPSF6 was determined by subtracting the CPSF6 binaries from ones colocalized with Hoechst (nucleus) signal. Mean intensity and volume were recorded for each binary. Virus localization was determined with the spot detection function to create binary masks for spots positive for mRuby3/tagRFP, FAP-GPI, CypA-DsRed, or p24 signals. Traf3LP1 and data analysis.

**Protein expression and purification.** The full-length CPSF6 protein was expressed in a suspension-adapted HEK293 cell line (ExpI 293F; Thermo Fisher Scientific) by transfection of expression plasmid using ExpIfectamine 293 (Thermo Fisher Scientific) according to the manufacturer’s instructions. Following transfection, the cells were grown at 37°C by shaking at 125 rpm in 8% CO2 and 80% humidity for 2 days. The cells were harvested after 48 h of transfection by centrifugation at 100 × g for 10 min. The cell pellet was washed with cold PBS and flash-frozen and stored at −80°C. The thawed cell pellet was resuspended in buffer A (50 mM HEPES-KOH [pH 8], 500 mM NaCl, and 5% glycerol, 2 mM dithiothreitol [DTT]) supplemented with detergents (1% Tween 20 and 0.3% NP-40) and DNase I (50 μg/ml; Sigma-Aldrich) in the presence of a cocktail of protease inhibitors (Roche). After 2 h of rotation at 4°C, the lysate was homogenized by 15 strokes in an ice-cold, tight-fitting Dounce homogenizer. The homogenate was then centrifuged at 21,000 × g at 4°C for 30 min. After centrifugation, the supernatant was collected and mixed with 1 ml of amyllose agarose resin (New England Biolabs) pre-equilibrated with buffer A per 50 ml of cell homogenate. The mixture was incubated with rotation at 4°C for 2 h and then transferred to a column. The resin was washed with 50 × volume resin volume of buffer A. To elute the recombinant protein, the resin was incubated with buffer A containing 100 mM maltose for 15 min at 4°C, and the flowthrough was collected as eluate. The eluate was applied to a Ni-Load Superdex 200 16/60 column (GE Healthcare) in a buffer A, and fractions containing target protein were collected and concentrated to 6 to 8 mg/ml using Amicon concentrators (Millipore, Billerica, MA, USA), flash-frozen with liquid nitrogen, and stored at −80°C. His-tagged CypA-DsRED-Exp2 was expressed in Escherichia coli Rosetta 2 (DE3) cells (EMD Millipore) with autoinduction medium at 18°C for 16 h. Protein was purified using 5 ml Ni-NTA column (GE Healthcare) and a HiLoad Superdex 200 16/60 size exclusion column (GE Healthcare) equilibrated with a buffer containing 25 mM sodium phosphate, pH 7.5, 150 mM NaCl, 1 mM dithiothreitol (DTT), 10% glycerol, and 0.02% sodium azide.

**SDS-PAGE and Western blot analysis.** For in vitro CPSF6 experiments, an equal volume of cell lysate and each fraction from the column were mixed with 4 × NuPAGE lithium dodecyl sulfate (LDS) sample buffer (Thermo Fisher Scientific) supplemented with 10 mM DTT and loaded onto a 10% Bis-Tris NuPAGE gel (Thermo Fisher Scientific), alongside a protein molecular weight marker (BLUEstain protein ladder; Gold Biotechnological). Gels were run at 100 V for 15 min and then 150 V for 40 min in NuPAGE morpholineethanesulfonic acid (MES) SDS running buffer, and the proteins were subsequently transferred onto PVDF or nitrocellulose membranes using iBlot transfer stacks (Thermo Fisher Scientific). The membranes were blocked at ambient temperature for 1 h in bovine serum albumin (BSA) blocking.
buffers, followed by overnight incubation at 4°C with rabbit anti-maltose binding protein antibody (ab9084; Abcam) or rabbit anti-CPSF6 antibody (EPR12898; Abcam) and then a further hour with monoclone anti-rabbit immunoglobulins-alkaline phosphatase antibody at ambient temperature. Between each antibody incubation, the membranes were washed three times with Tris-buffered saline (TBS) buffer containing 0.1% Tween 20, and finally, the membranes were developed with BCIP (5-bromo-4-chloro-3-indolylphosphate)/nitroblue tetrazolium (NBT) color development substrate (Promega) to enable visualization of protein bands (Promega, USA). Each experiment was performed at least three times.

For measurement of CPSF6 expression in cells, an equal number of transduced and puromycin-selected HeLa cells or PBMCs were lysed with RIPA buffer (Bio-Rad), mixed with sample buffer (Bio-Rad), and heated to 100°C for 5 min. Denatured cell lysate was run on precasted 4 to 15% Criterion Tris-HCl gels (Bio-Rad) at 150 V for 1.5 h. Proteins were transferred to nitrocellulose membranes using a semi-dry transfer apparatus (Thermo Fisher Scientific) at 160 mA for 1 h. The membranes were blocked with 5% milk in PBS containing 0.1% Tween 20 at room temperature for 20 min. The primary antibodies anti-CPSF6 (NB1-85676) and anti-α-tubulin (T5168; Sigma-Aldrich) were used with secondary anti-mouse IgG or anti-rabbit IgG conjugated with horseradish peroxidase antibodies (A9917 and AP132P; Sigma-Aldrich). SuperSignal West Pico chemiluminescent substrate (Thermo Fisher Scientific) was used to visualize protein bands with Amersham hyperfilm (GE).

**Capsid binding assay.** Tubular assemblies of WT HIV-1 CA protein were prepared at 80 μM (2 mg/ml) in 1 M NaCl and 50 mM Tris-HCl (pH 8.0) buffer at 37°C for 1 h. N74D CA was dialyzed against 1 M NaCl and 50 mM Tris-HCl (pH 8.0) buffer at 4°C overnight at the concentration of 20 mg/ml. Before binding, the assembled mixture was diluted to 80 μM (2 mg/ml). For the binding assays, the binding buffer was the same as the stock buffer for MBP-CPSF6 proteins described above. Different concentrations of MBP-CPSF6 were added to preassembled CA tubes at a CA concentration of 64 μM. The reaction mixtures were incubated on a rocking platform at room temperature for 1 h with gentle mixing at 10-min intervals. Then, 5-μl samples were withdrawn from the reaction mixtures and immediately used for electron microscopy (EM) analysis. The remaining samples were pelleted at 21,000 × g for 30 min, supernatants (s) and pellets (p, resuspended in the same volume) were mixed with 4 × LDS loading buffer for gel analysis. Supernatant and pellet samples, without boiling, were loaded on 10% SDS-PAGE and stained with Coomassie blue. Each experiment was performed at least three times.

To determine the binding ratio of MBP-CPSF6:CA, SDS-PAGE gels were scanned using an Epson 4990 scanner. The integrated intensities of CA and MBP-CPSF6 protein bands were measured using the ImageJ 1.40 program (NIH). The molar ratios were calculated according to the formula (MBP-CPSF6 intensity/MBP-CPSF6 molecular weight)/(CA intensity/CA molecular weight) and calibrated using the input ratios as standards.

For binding of CypA and MBP-CPSF6 with HIV-1 capsid, 5 μM CypA-DsRed was added to 10 μM preassembled WT CA-NC tubes, and at the same time 15 μM competitive inhibitor CsA was added as a negative control. The reaction mixtures were incubated on a rocking platform at room temperature for 1 h with gentle mixing at 10-min intervals. Then, 5 μM MBP-CPSF6 P1 or P2 was added to the reaction and incubated on a rocking platform at room temperature for 1 h with gentle mixing at 10-min intervals. At the end of the incubation, the samples were pelleted as described above. Each experiment was performed at least three times. Nikon Elements 5.0 was used to quantify the binding ratio of CypA and MBP-CPSF6 with preassembled CA-NC tubes.

**TEM analysis.** The morphologies of different variants of CA assemblies and CA–MBP-CPSF6 complexes were characterized by TEM. Samples were stained with fresh 2% uranyl formate, deposed onto 400-mesh carbon-coated copper grids, and dried for 30 min. TEM images were acquired on a Tecnai T12 transmission electron microscope at 120 kV.

**Statistics.** Each virus infection experiment and associated imaging analysis was performed in at least two separate replicates. Collected data were obtained from at least two independent experiments or three donors. Statistical significance was determined by two-sided unpaired Student’s t-test using Prism (GraphPad). P values of <0.05 were considered statistically significant. ns, P > 0.05; *, P = 0.01 to 0.05; ***, P = 0.01 to 0.001; ****, P = 0.001 to 0.0001; *****, P < 0.0001.

**SUPPLEMENTAL MATERIAL**

Supplemental material is available online only.

**MOVIE S1**, MOV file, 0.5 MB.
**MOVIE S2**, MOV file, 1 MB.
**MOVIE S3**, MOV file, 2.4 MB.
**MOVIE S4**, MOV file, 4.2 MB.
**FIG S1**, JPG file, 0.2 MB.
**FIG S2**, JPG file, 0.2 MB.
**FIG S3**, JPG file, 0.5 MB.
**FIG S4**, JPG file, 0.2 MB.
**FIG S5**, JPG file, 0.3 MB.
**FIG S6**, JPG file, 0.2 MB.
Acknowledgments

We thank Stephanie Ander, Douglas Fischer, Sharie Ganchua, and Chris Kline for technical assistance and Vineet KewalRamani, Ned Landau, Greg Melikian, and Greg Towers for refrares.

This work was supported by National Institutes of Health (NIH) P50 grant AI150481 (A.N.E., P.Z., S.C.W., and Z.A.), NIH R01 grant AI052014 (A.N.E.), NIH R01 grant GM114075 (C.T. and M.P.B.), NIH T32 training grant AI065380 (E.A.B.), and the UK Wellcome Trust Investigator Award 206422/Z/17/Z (P.Z.).

Conceptualization: Z.Z., P.Z., S.C.W., Z.A.; investigation: Z.Z., J.N., E.A.B., C.W.; resources: S.J., C.T., M.P.B., J.A., A.N.E.; supervision: P.Z., S.C.W., Z.A.; writing, original draft: Z.Z., J.N., Z.A.; writing, review and editing: all authors.

References

1. Ganser BK, Li S, Klishko VF, Finch JT, Sundquist WI. 1999. Assembly and analysis of conical models for the HIV-1 core. Science 283:80–83. https://doi.org/10.1126/science.283.5398.80.
2. Zhao G, Perilla JR, Yufenyuy EL, Meng X, Chen B, Ning J, Ahn J, Gronenborn AM, Schulten K, Aiken C, Zhang P. 2013. Mature HIV-1 capsid structure by cryo-electron microscopy and all-atom molecular dynamics. Nature 497:643–646. https://doi.org/10.1038/nature12162.
3. Ambrose Z, Aiken C. 2014. HIV-1 uncoating: connection to nuclear entry and regulation by host proteins. Virology 454:455–379. https://doi.org/10.1016/j.virol.2014.02.004.
4. Campbell EM, Hope TJ. 2015. HIV-1 capsid: the multifaceted key player in HIV-1 infection. Nat Rev Microbiol 13:471–483. https://doi.org/10.1038/nrmicro3503.
5. Lukic Z, Dharan A, Fricke T, Diaz-Griffero F, Campbell EM. 2014. HIV-1 uncoating is facilitated by dynein and kinesin 1. J Virol 88:13613–13625.
6. Malikov V, Naganlstock A, Suijs-Cremer N, Ambrose Z. 2013. Evidence for biphasic uncoating during HIV-1 infection from a novel imaging assay. Retrovirology 10:70. https://doi.org/10.1186/1742-4690-10-70.
7. Bukrinsky MI, Sharova N, Dempsey MP, Stanwick TL, Bukrinskaya AG, Waring C, Watkins S, Sluijs-Cremer N, Ambrose Z. 2013. Evidence for biphasic uncoating, and nuclear transport. Cell Host Microbe 23:536–549. https://doi.org/10.1016/j.chom.2018.03.009.
8. Xu H, Frankis T, Gibson G, Huber K, Rahm N, De Castillia CS, Luban J, Aiken C, Watkins A, Suijs-Cremer N, Ambrose Z. 2013. Evidence for biphasic uncoating during HIV-1 infection from a novel imaging assay. Retrovirology 10:70. https://doi.org/10.1186/1742-4690-10-70.
9. Braaten D, Franke EK, Luban J. 1996. Cyclophilin A is required for an early step in the life cycle of human immunodeficiency virus type 1. J Virol 70:3551–3560. https://doi.org/10.1128/JVI.70.6.3551-3560.1996.
10. De Iaco A, Luban J. 2014. Cyclophilin A promotes HIV-1 reverse transcription. J Virol 78:12808–12808. https://doi.org/10.1128/JVI.78.23.12808-12808.2004.
11. Qi M, Yang R, Aiken C. 2008. Cyclophilin A-dependent restriction of human immunodeficiency virus type 1 infectivity. J Virol 78:12800–12801. https://doi.org/10.1128/JVI.78.23.12800-12801.2004.
12. Braaten D, Franke EK, Luban J. 1996. Cyclophilin A is required for an early step in the life cycle of human immunodeficiency virus type 1. J Virol 70:3551–3560. https://doi.org/10.1128/JVI.70.6.3551-3560.1996.
13. Weigges K, Rutter G, Schubert U, Grattinger M, Krausslich HG. 1999. Cyclophilin A incorporation is not required for human immunodeficiency virus type 1 particle maturation and does not destabilize the mature capsid. Virol 257:261–274. https://doi.org/10.1002/vice.109999669.
14. Sokolskaja E, Suyah DM, Luban J. 2004. Target cell cyclophilin A modulates HIV-1 infection. Trends Microbiol 12:1581–1582. https://doi.org/10.1016/j.tim.2004.04.004.
15. Yamashita M, Engelman AN. 2017. Capsid-dependent host factors in HIV-1 infection. Trends Microbiol 25:751–755. https://doi.org/10.1016/j.tim.2017.04.004.
16. Luban J, Bossolt KL, Franke EK, KalpanaGV, Goff SP. 1993. Human immunodeficiency virus type 1 Gag protein binds to cyclophilins A and B. Cell 73:1067–1078. https://doi.org/10.1016/0092-8674(93)90637-6.
17. Gamble TR, Vajdos FF, Yoo S, Worthylake DK, Houseweart M, Sundquist WI, Hill CP. 1996. Crystal structure of human cyclophilin A bound to the amino-terminal domain of HIV-1 capsid. Cell 87:1285–1294. https://doi.org/10.1016/s0092-8674(00)81823-1.
18. Koletsky AJ, Harding MW, Handschumacher RE. 1986. Cyclophilin: distribution and variant properties in normal and neoplastic tissues. J Immunol 137:1054–1059.
19. Lee K, Ambrose Z, Martin TD, Oztot I, Mulky A, Julias JG, Wang R, Yuen W, Takemura T, Shelton K, Tanitchi I, Li Y, Sodroskij L, Littman DR, Coffin JM, Hughes SH, Unutmaz D, Engelman A, KewalRamani VN. 2010. Flexible use of nuclear import pathways by HIV-1. Cell Host Microbe 7:221–233. https://doi.org/10.1016/j.chom.2010.02.007.
20. Franke EK, Yuan HE, Luban J. 1994. Specific incorporation of cyclophilin A into HIV-1 virions. Nature 372:359–362. https://doi.org/10.1038/372359a0.
21. Kim K, Dauphin A, Komurlu S, McCauley SM, Yurkovetskiy L, Carbone C, Rixon FJ, Bieniasz PD. 2013. Extreme genetic fragility of the HIV-1 capsid. Cell 155:3026–3037. https://doi.org/10.1016/j.cell.2013.10.009.
22. Diehl WE, Strambio-De-Castillia C, Campbell EM, Luban J. 2019. Cyclophilin A prevents HIV-1 restriction in lymphocytes by blocking human TRIM5alpha binding to the viral core. Cell Rep 30:3766–3777. https://doi.org/10.1016/j.celrep.2020.02.100.
31. Dettwiler S, Aringhieri C, Cardinale S, Keller W, Barabino SM. 2004. Distinct sequence motifs within the 68-69kDa subunit of cleavage factor Im mediate RNA binding, protein-protein interactions, and subcellular localization. J Biol Chem 279:35788–35797. https://doi.org/10.1074/jbc.M403927200.

32. Price AJ, Fletcher AJ, Schaller T, Elliott T, Lee K, Kawarlamani VN, Chinn JW, Towers GJ, James LC. 2012. CPSF6 defines a conserved capsid interface that modulates HIV-1 replication. PLoS Pathog 8:e1002896. https://doi.org/10.1371/journal.ppat.1002896.

33. Jang S, Cook NJ, Pye VE, Bedwell DJ, Dudek AM, Singh PK, Cherepanov P, Engelmann AN. 2019. Differential role for phosphorylation in alternative polyadenylation function versus nuclear import of SR-like protein CPSF6. Nucleic Acids Res 47:4663–4683. https://doi.org/10.1093/nar/gkz206.

34. Maertens GN, Cook NJ, Wang W, Hare S, Gupta SS, Oztop I, Lee K, Pye VE, Cosnefroy O, Snijders AP, Kawarlamani VN, Fassati A, Engelmann A, Cherepanov P. 2014. Structural basis for nuclear import of splicing factors by human transportin 3. Proc Natl Acad Sci U S A 111:2728–2733. https://doi.org/10.1073/pnas.1320755111.

35. De lao A, Santoni F, Vannier A, Guipponi M, Antonaridis S, Luban J. 2013. TNPO3 protects HIV-1 replication from CPSF6-mediated capsid stabilization in the host cell cytoplasm. Retrovirology 10:20. https://doi.org/10.1186/1742-4690-10-20.

36. Fricke T, Valle-Casuso JC, White TE, Brandariz-Nunez A, Bosche WJ, Reszka N, Coreckli R, Diaz-Galofaro F. 2013. The ability of TNPO3-depleted cells to inhibit HIV-1 infection requires CPSF6. Retrovirology 10:46. https://doi.org/10.1186/1742-4690-10-46.

37. Price AJ, Jacques DA, McEwan WA, Fletcher AJ, Essig S, Chin JW, Halambage UD, Aiken C, James LC. 2014. Host cofactors and pharmacologic ligands share an essential interface in HIV-1 capsid that is lost upon disassembly. PLoS Pathog 10:e1004459. https://doi.org/10.1371/journal.ppat.1004459.

38. Henning MS, Dubose BN, Burke MJ, Aiken C, Yamashita M. 2014. In vivo functions of CPSF6 for HIV-1 as revealed by HIV-1 capsid evolution in HLA-B27-positive subjects. PLoS Pathog 10:e1003868. https://doi.org/10.1371/journal.ppat.1003868.

39. Saito A, Henning MS, Serra O, Dubose BN, Teng S, Huang J, Li X, Saito N, Roy SP, Siddiqui MA, Ahn J, Tsuji M, Hatziioannou T, Engelmann AN, Yamashita M. 2016. Capsid-CPSF6 interaction is dispensable for HIV-1 replication in primary cells but is selected during virus passage in vivo. J Virol 90:6918–6935. https://doi.org/10.1128/JVI.00019-16.

40. Sowd GA, Serra O, Wang H, Wang W, Fadel HJ, Poeschla EM, Engelmann AN. 2016. A critical role for alternative polyadenylation factor CPSF6 in targeting HIV-1 integration to transcriptionally active chromatin. Proc Natl Acad Sci U S A 113:E1054–E1063. https://doi.org/10.1073/pnas.1524213113.

41. Achuthan V, Perreira JM, Savidis G, Portmann JM, Aker AM, Feeley EM, Smith GB. 2020. HIV-1 replication complexes accumulate in nuclear speckles and integrate into speckle-associated genomic domains. Nat Commun 11:3505. https://doi.org/10.1038/s41467-020-17256-8.

42. Francis AC, Marin M, Prellberg MJ, Palermino-Rowland K, Lan S, Tedbury PR, Sarafanos SG, Engelmann AN, Melikyan GB. 2020. HIV-1 replication complexes accumulate in nuclear speckles and integrate into speckle-associated genomic domains. Nat Commun 11:3505. https://doi.org/10.1038/s41467-020-17256-8.

43. Yamashita M, Perez O, Hope TJ, Emerman M. 2007. Evidence for direct involvement of the capsid protein in HIV infection of nondividing cells. PLoS Pathog 3:1502–1510. https://doi.org/10.1371/journal.ppat.0030156.

44. Dhawan A, Bachmann N, Talley S, Zwikkelmaier V, Campbell EM. 2020. Nuclear pore blockade reveals that HIV-1 completes reverse transcription and uncoating in the nucleus. Nat Microbiol 5:1088–1095. https://doi.org/10.1038/s41564-020-0735-8.

45. Francis AC, Marin M, Singh PK, Achuthan V, Prellberg MJ, Palermino-Rowland K, Lan S, Tedbury PR, Sarafanos SG, Engelmann AN, Melikyan GB. 2020. HIV-1 replication complexes accumulate in nuclear speckles and integrate into speckle-associated genomic domains. Nat Commun 11:3505. https://doi.org/10.1038/s41467-020-17256-8.

46. Francis AC, Marin M, Prellberg MJ, Palermino-Rowland K, Melikyan GB. 2020. HIV-1 Uncoating and nuclear import preclude the completion of reverse transcription in cell lines and in primary macrophages. Viruses 12:1234. https://doi.org/10.3390/v12111234.

47. Peng K, Muranyi W, Glass B, Laketa V, Yant SR, Tsai L, Cihlar T, Muller B, Krausslich HG. 2014. Quantitative microscopy of functional HIV post-entry complexes reveals association of replication with the viral capsid. Elife 3:e04114. https://doi.org/10.7554/eLife.04114.

48. Lee PP, Linial ML. 1994. Efficient particle formation can occur if the matrix domain of human immunodeficiency virus type 1 Gag is substituted by a myristylation signal. J Virol 68:6644–6654. https://doi.org/10.1128/JVI.68.11.6644-6654.1994.

49. Rasaiyaah J, Tan CP, Fletcher AJ, Price AJ, Blondeau C, Hilditch L, Jacques DA, Selwood DL, James LC, Noursadeghi M, Towers GJ. 2013. HIV-1 evolves innate immune recognition through specific cofactor recruitment. Nature 503:402–405. https://doi.org/10.1038/nature12769.

50. Byeon IU, Meng X, Jung J, Zhao G, Yang R, Ahn J, Shin J, Concel J, Aiken C, Zhang P, Gronenborn AM. 2009. Structural convergence between Cryo-EM and NMR reveals intersubunit interactions critical for HIV-1 capsid function. Cell 139:780–790. https://doi.org/10.1016/j.cell.2009.10.010.

51. Meng X, Zhao G, Yufenyuy E, Ke D, Ning J, Delucia M, Ahn J, Gronenborn AM, Aiken C, Zhang P. 2012. Protease cleavage leads to formation of immature virus type 1 Gag is substituted by a myristylation signal. J Virol 68:6644–6654. https://doi.org/10.1128/JVI.68.11.6644-6654.1994.

52. Francis AC, Marin M, Singh PK, Achuthan V, Prellberg MJ, Palermino-Rowland K, Melikyan GB. 2020. HIV-1 Uncoating and nuclear import preclude the completion of reverse transcription in cell lines and in primary macrophages. Viruses 12:1234. https://doi.org/10.3390/v12111234.

53. Ning J, Zhong Z, Fischer DK, Harris G, Watkins SC, Ambrose Z, Zhang P. 2018. Matured capsid-CPSF6 forms higher-order complexes that bind and disrupt HIV-1 capsid. J Virol 92:e00368-18. https://doi.org/10.1128/JVI.00368-18.

54. Caras IW. 1991. An internally positioned signal can direct attachment of a glycoporphin C membrane anchor. J Cell Biol 113:77–85. https://doi.org/10.1083/jcb.113.1.77.

55. Matreyek KA, Yucek SS, Li X, Engelmann A. 2013. Nucleoprotein NUP153 phe- nylalanine-glycine motifs engage a common binding pocket within the HIV-1 capsid protein to mediate lentiviral infectivity. PLoS Pathog 9: e1003693. https://doi.org/10.1371/journal.ppat.1003693.

56. Francis AC, Marin M, Shi J, Aiken C, Melikyan GB. 2016. Time-resolved imaging of single HIV-1 uncoating in vitro and in living cells. PLoS Pathog 12:e1005709. https://doi.org/10.1371/journal.ppat.1005709.

57. Sokolskaja E, Berthoux L, Luban J. 2006. Cyclophilin A and TRIM34 alpha independently regulate human immunodeficiency virus type 1 infectivity in human cells. J Virol 80:2855–2862. https://doi.org/10.1128/JVI.80.6.2855-2862.2006.